Navigation Links
Definitive study confirms chemo benefit in postmenopausal breast cancer
Date:12/10/2009

ANN ARBOR, Mich. Chemotherapy added to tamoxifen can improve outcomes for postmenopausal breast cancer patients, according to a landmark study by the Southwest Oncology Group.

But a related study presented today at the 2009 San Antonio Breast Cancer Symposium finds that a multigene test on tumors can identify a subset of patients who may not benefit from that chemotherapy.

Both studies were led by Dr. Kathy Albain, of Loyola University Health System. Both have just been published online, the first in the journal the Lancet, the second in the Lancet Oncology.

The studies report on a randomized phase III clinical trial of 1,477 postmenopausal women that was conducted at institutions across the U.S. and Canada by the University of Michigan-based Southwest Oncology Group (SWOG), one of the largest federally funded clinical trial networks. All of the women had estrogen receptor-positive (ER+) breast cancer that had spread to the lymph nodes under the arm, known as the axillary lymph nodes.

All women in the trial got daily tamoxifen for up to five years, long the standard therapy for treating ER+ breast cancer, the most common form of the disease. Estrogen latches on to receptors on these cancer cells and promotes tumor growth. Tamoxifen blocks those receptors, locking estrogen out.

Of the 1,477 women in the trial, 361 got only tamoxifen. The rest got tamoxifen plus a regimen of a three-drug chemotherapy treatment known as CAF (cyclophosphamide, Adriamycin, and 5-fluorouracil).

Albain's team reports in the Lancet paper that they saw long-term survival benefits for the women who received CAF chemotherapy. These women's risk of dying or having a cancer recurrence was 24% lower than it was for women who had gotten tamoxifen alone. The team also found that those who got the chemotherapy before the tamoxifen did better than those who got both simultaneously.

The CAF group had higher over
'/>"/>

Contact: Frank DeSanto
fdesanto@umich.edu
734-998-0114
University of Michigan Health System
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions
2. Authentidate Introduces New Interface for Inscrybe Healthcare with Definitive Homecare Solutions CPR+
3. Kimberly-Clark Announces Definitive Agreement to Acquire I-Flow Corporation
4. Definitive Sexual Health Book Released
5. Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimers Immunotherapy Program and Equity Investment
6. Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
7. Triple-S Management Corporation Announces Execution of Definitive Agreement to Acquire Managed Care Portfolio of La Cruz Azul de Puerto Rico, Inc.
8. Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion
9. AMICAS Announces Definitive Agreement to Acquire Emageon Inc.
10. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
11. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , ... July 27, 2015 , ... ... Step One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. ... of the first things FDA investigators will look at during an inspection. ...
(Date:7/27/2015)... ... July 27, 2015 , ... On July 14, 2015, Harper’s Bazaar ... Issues,” describes common skin issues such as stretch marks , fine lines ... treat them. The treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital will be holding ... all those prospective joint-replacement patients, along with their friends and family members, to attend. ... classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct 5, Nov 2, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... David Gilmour ... He will be performing for one additional night at each of his original four ... DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing ... to its options. Already an industry leader because of its use of ... for the latest successful trends in helping people to overcome addiction and live ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... Most of the 28 million Americans living with untreated ... corrective action could result in the brain actually "forgetting" how ... , Dr. Beyer is senior vice president of HearUSA (Amex: ... hearing aids companies. , "When the brain is insufficiently stimulated ...
... Fla., Oct. 19 Blue Cross and ... statewide Medicare Advantage Regional PPO plan called BlueMedicare Regional ... offerings for Florida,s Medicare eligibles. The BlueMedicare Regional PPO ... Private Fee-for-Service, Part D and Medicare Supplement plans. , ...
... ... the world,s leading manufacturer and distributor of health testing stations and automated blood pressure ... with UnitedHealth Group,s Passport to Health and Well Being at the 2009 AARP Vegas@50+ ... ...
... ... Biodiagnostics, Inc., today announced that the U.S. Food and Drug Administration ... 15 monoclonal antibodies in its proprietary line of transfusion diagnostics. ... and hospitals to type and screen blood. Quotient Biodiagnostics was formed ...
... CITY, Kan., Oct. 19 Premier Plastic Surgery of Kansas City, ... has redesigned its extensive website to include a separate section ... and a Plastic Surgery Blog that features breaking news on ... Society for Aesthetic Plastic Surgery, cosmetic surgery for males increased ...
... and men have opposing views on many topics, and it ... pain. According to a new survey of women and men ... leading independent health information source for women, women are more ... have a higher tolerance for pain (76% versus 32%, respectively)(1).In ...
Cached Medicine News:Health News:If Hearing Loss is Not Treated, Brain Can 'Forget' How to Hear and Understand Speech 2Health News:Blue Cross and Blue Shield of Florida Now Offers More Choices to Florida's Seniors 2Health News:Blue Cross and Blue Shield of Florida Now Offers More Choices to Florida's Seniors 3Health News:Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 2Health News:Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 3Health News:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market 2Health News:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market 3Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 2Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 3Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 4Health News:Women and Men Face Off: Who Can Stand the Pain? 2Health News:Women and Men Face Off: Who Can Stand the Pain? 3
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: